An updated patent review of GLP-1 receptor agonists (2020-present)
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Type 2 diabetes (T2DM) and obesity present significant global health issues, requiring the development of long-lasting and highly effective pharmacotherapies. Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used for diabetes treatment, their potential for addressing obesity is still being explored. AREAS COVERED: This review offers a comprehensive overview of recently published patents from January 2020 to July 2023, focusing on modified GLP-1RAs, small molecule GLP-1RAs, GLP-1 R-based multi-agonists, GLP-1RA-based fusion proteins, and combination therapies. The patents discussed pertain to the treatment and prevention of diabetes and obesity. Patent searches were conducted using the PATENTSCOPE database of the World Intellectual Property Organization, using the keywords GLP-1, GLP-1/GIP, GLP-1/GCG, and GLP-1/GCG/GIP. EXPERT OPINION: In recent years, patents have emphasized two main goals for developing GLP-1RAs drugs: oral delivery and improved weight reduction effects. To address the growing demand for improved treatments, researchers have focused their efforts on developing GLP-1 R-based multi-agonists, orally administered GLP-1RAs, and combination therapies utilizing GLP-1RAs. These new approaches offer promising benefits, such as improved effectiveness by targeting multiple pathways and reduced side effects. Additionally, the development of new uses, oral forms, and long-lasting preparations will be crucial in shaping the future market potential of GLP-1 drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Moreover, the recently approved high-dose version of the once-weekly GLP-1RA semaglutide, available in a dosage of 2.4 mg (marketed as Wegovy), further elevates the average weight reduction to a range of 15–20% within this patient population [22].”
BackgroundInfluentialObesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 1×
“Obesity is a major contributor to global morbidity and mortality as it serves as a catalyst for numerous comorbidities including nonalcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM), cardiovascular disease, hypercholesterolemia, hypertension, and cancer [2–4].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Studies have shown that GIP also modulates glucagon secretion in a glucose-dependent manner, facilitating the clearance of lipids following a meal, and regulating food intake (Figure 3) [65].”
BackgroundGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“In this context, the appetite-suppressive effects of glucagon-like peptide-1 (GLP-1) and its analogues have proved valuable and are now approved for obesity treatment, having been in clinical use for T2DM for over a decade [7,8].”
BackgroundObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Furthermore, GLP-1 hinders gastric emptying, induces feelings of satiety, and ultimately leads to a decrease in body weight [9].”
BackgroundAnti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 4×
“…to bridge this divide, researchers have explored the concept of the ‘co-agonist’ strategy, which involves blending GLP-1 with other hormones from the proglucagon family, as well as related peptides such as glucagon, glucose-dependent insulinotropic polypeptide (GIP) and amylin analogues [28–30].”
BackgroundInfluentialThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Research works printed but not linked: 6
- Hanmi Pharm. Co., Ltd. Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof. WO2020263063. 2020.
- Shenzhen Deeply-invasive Biopharmaceutical Co., Ltd. GLP-1R/GCGR/GIPR triple receptor agonist and application thereof. CN114437181A. 2022.
- The United Bio-technology (Hengqin) Co., Ltd. Multi-agonist and use thereof. WO2022247701. 2022.
- Jiangsu Chinese New Medicine Co., Ltd. GLP-1, GIP and GCG multiple receptor agonist proteins. CN114621327A. 2022.
- Heptares Therapeutics Limited. Oral GLP receptor agonists. WO2021186169. 2021.
- Janssen Pharmaceutica. Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof. CN112004822A. 2020.
Cited by
Moiz, A., Filion, K. B., Toutounchi, H., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01590 · Cited by 149
Guo, H., Yang, J., Huang, J., Xu, L., Lv, Y., Wang, Y., Ren, J., Feng, Y., Zheng, Q., & Li, L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100162 · Cited by 32
“Clinical trials for GLP-1/GIP/GCG triple agonists are ongoing [19].”
Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
Padmanaban, S., Baek, J.-W., Sahithya, C. S., Saipriya, C., Samrot, A. V., Gosu, V., Park, I., Radhakrishnan, K., & Kim, D. (2025) · Liver Research · doi:10.1016/j.livres.2025.04.002 · Cited by 22
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Self-citation
Metadata
- Authors
- Lu, W., Zhou, Z., Jiang, N., & Han, J.
- Affiliations
- Guangxi Medical University (CN)
- Youjiang Medical College for Nationalities (CN)
- Jiangsu Normal University (CN)
- Corresponding author
- Zhou, Zhongbo
- Jiang, Neng
- Han, Jing
- ORCID
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2023-09-02
- Volume
- 33
- Issue
- 9
- Pages
- 597-612
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W4387866199
- Cited by
- 17
- References
- 72
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 4
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Patents (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Guangxi Science Fund for Distinguished Young Scholars (2022GXNSFFA035030)
- Special Funds for Science and Technology Development under the Guidance of the Central Government (ZY20198020)
- National Natural Science Foundation of China (82173663)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, GIP/GLP-1 receptor agonist, combination therapy, sustained drug release, weight loss, pharmaceutical patents
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Patents as Topic, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An updated patent review of GLP-1 receptor agonists (2020-present). https://app.cochat.ai/papers/10.1080/13543776.2023.2274905
- The paper
- Lu, W., Zhou, Z., Jiang, N., & Han, J. (2023). An updated patent review of GLP-1 receptor agonists (2020-present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2023.2274905
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.